At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
Riluzole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder
Uniformed Services University of the Health Sciences·interventional·Posted Jun 4, 2014·Updated May 24, 2021
In Brief
A Phase 2 clinical trial evaluating Riluzole and Placebo (for Riluzole) for PTSD. Completed, enrolled 75 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether Riluzole is effective in the augmentation treatment of post-traumatic stress disorder (PTSD) that is experienced by Active Duty military service members and Operation Enduring Freedom (OEF), Operation Iraqi Freedom (OIF), and Operation New Dawn (OND) veterans who have not had symptom reduction after one or more kinds of medications or therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPTSD
CountriesUnited States
CollaboratorsU.S. Army Medical Research and Development Command
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJun 2014
Primary CompletionOct 2017
Study CompletionNov 2017
TodayJul 2026
First PostedJun 4, 2014
Enrollment StartJul 1, 2013
Primary CompletionOct 30, 2017
Study CompletionNov 30, 2017
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.1 years ago
Interventions
Riluzoledrug
Placebo (for Riluzole)drug